Shares of UCB SA (OTCMKTS:UCBJY – Get Free Report) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $95.03 and traded as high as $95.64. UCB shares last traded at $94.71, with a volume of 5,059 shares.
UCB Stock Performance
The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The company’s fifty day simple moving average is $95.03 and its 200-day simple moving average is $86.55.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- Top Stocks Investing in 5G Technology
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- How to Invest in Biotech Stocks
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How to Invest in Insurance Companies: A Guide
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
